Almirall has licensed global rights to its DHODH (dihydroorotate dehydrogenase) inhibitor LAS186323, which is currently in Phase I development for rheumatoid arthritis, to Singapore-based ASLAN Pharmaceuticals. The deal is consistent with ASLAN’s strategy of advancing deprioritised early-stage programmes through Phase II proof-of-concept trials in Asia before licensing them back to the discoverer or seeking a partner for late-stage development and commercialisation.